{"id":52147,"date":"2025-12-29T12:51:19","date_gmt":"2025-12-29T04:51:19","guid":{"rendered":"https:\/\/flcube.com\/?p=52147"},"modified":"2025-12-29T12:51:19","modified_gmt":"2025-12-29T04:51:19","slug":"innovent-biologics-secures-nmpa-approval-for-tabosun-as-first-neoadjuvant-dual-io-therapy-for-msi-h-dmmr-colon-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52147","title":{"rendered":"Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual\u2011IO Therapy for MSI\u2011H\/dMMR Colon Cancer"},"content":{"rendered":"\n<p><strong>Innovent Biologics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1801:HKG\">HKG: 1801<\/a>) announced that <strong>China\u2019s National Medical Products Administration (NMPA)<\/strong> has approved the <strong>New Drug Application (NDA)<\/strong> for <strong>TABOSUN (ipilimumab N01 injection; IBI310)<\/strong>, a <strong>first\u2011in\u2011class domestic CTLA\u20114 monoclonal antibody<\/strong>, to be used in combination with the PD\u20111 inhibitor <strong>sintilimab<\/strong> as <strong>neoadjuvant treatment<\/strong> for adult patients with <strong>stage IIB\u2011III resectable microsatellite instability\u2011high (MSI\u2011H) or mismatch repair deficient (dMMR) colon cancer<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Approval Authority<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>TABOSUN (ipilimumab N01 injection)<\/td><\/tr><tr><td><strong>Mechanism of Action<\/strong><\/td><td>CTLA\u20114 monoclonal antibody<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Neoadjuvant therapy + sintilimab for stage IIB\u2011III resectable MSI\u2011H\/dMMR colon cancer<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>25\u202fDec\u202f2025<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>World\u2019s first approved dual\u2011IO neoadjuvant regimen<\/strong> for MSI\u2011H\/dMMR colon cancer; <strong>first domestic anti\u2011CTLA\u20114 mAb<\/strong> in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-strategic-position\">Drug Profile &amp; Strategic Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Discovery &amp; IP<\/strong>: Fully in\u2011house discovery by Innovent; strengthens its <strong>sintilimab\u2011centric immuno\u2011oncology franchise<\/strong><\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Unlike imported CTLA\u20114 inhibitors (e.g., Bristol\u2011Myers Squibb\u2019s Yervoy), TABOSUN is manufactured and priced for the China market, offering potential cost advantages for hospital procurement<\/li>\n\n\n\n<li><strong>Combination Rationale<\/strong>: Dual checkpoint blockade (CTLA\u20114 + PD\u20111) has shown superior pathological response rates in MSI\u2011H\/dMMR tumors, which are highly immunogenic<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-neoshot-phase-3-trial-nct05890742\">Clinical Evidence \u2013 NeoShot Phase\u202f3 Trial (NCT05890742)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result (TABOSUN + Sintilimab)<\/th><th>Comparator (Direct Surgery)<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial Design<\/strong><\/td><td>Randomized, controlled, multicenter, pivotal Phase\u202f3<\/td><td>Direct radical surgery<\/td><\/tr><tr><td><strong>Evaluable Patients<\/strong><\/td><td>50 (interim analysis)<\/td><td>50 (interim analysis)<\/td><\/tr><tr><td><strong>Pathological Complete Response (pCR) Rate<\/strong><\/td><td><strong>82.0\u202f% (41\/50)<\/strong><\/td><td>Not applicable<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>No significant increase in Grade\u202f\u2265\u202f3 adverse events vs. surgery alone<\/td><td>Baseline surgical risk<\/td><\/tr><tr><td><strong>Key Secondary Endpoints<\/strong><\/td><td>Median DFS and OS under follow\u2011up; data expected H2\u202f2026<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The trial met its <strong>primary efficacy endpoint<\/strong> with a pCR rate that positions the regimen as a potential <strong>standard\u2011of\u2011care<\/strong> for this molecular subtype.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Incidence<\/strong>: China reports ~520,000 new colorectal cancer cases annually; <strong>MSI\u2011H\/dMMR prevalence<\/strong> is ~12\u201115\u202f% of stage\u202fII\u2011III cases, translating to <strong>~70,000 eligible patients per year<\/strong><\/li>\n\n\n\n<li><strong>Revenue Forecast<\/strong>: Innovent projects peak sales of <strong>\u00a52.5\u20113.0\u202fbillion<\/strong> (US$350\u2011420\u202fmillion) by 2028, assuming <strong>40\u201150\u202f% market share<\/strong> in the neoadjuvant MSI\u2011H segment and NRDL inclusion by 2027<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: <strong>No approved neoadjuvant immunotherapy<\/strong> for colon cancer in China; TABOSUN+sintilimab has a <strong>3\u2011year first\u2011mover advantage<\/strong> over potential rivals<\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: Expected WAC of <strong>\u00a580,000\u201190,000<\/strong> per treatment course (\u2248\u202fUS$11,200\u201112,600), ~30\u202f% below imported PD\u20111+CTLA\u20114 regimens<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements concerning Innovent\u2019s revenue expectations, market penetration, and clinical development plans for TABOSUN. Actual outcomes may differ due to regulatory, competitive, and reimbursement dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,29,910,107,198,15],"class_list":["post-52147","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-combination-therapy","tag-hkg-1801","tag-immunotherapy","tag-innovent-biologics","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual\u2011IO Therapy for MSI\u2011H\/dMMR Colon Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for TABOSUN (ipilimumab N01 injection; IBI310), a first\u2011in\u2011class domestic CTLA\u20114 monoclonal antibody, to be used in combination with the PD\u20111 inhibitor sintilimab as neoadjuvant treatment for adult patients with stage IIB\u2011III resectable microsatellite instability\u2011high (MSI\u2011H) or mismatch repair deficient (dMMR) colon cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52147\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual\u2011IO Therapy for MSI\u2011H\/dMMR Colon Cancer\" \/>\n<meta property=\"og:description\" content=\"Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for TABOSUN (ipilimumab N01 injection; IBI310), a first\u2011in\u2011class domestic CTLA\u20114 monoclonal antibody, to be used in combination with the PD\u20111 inhibitor sintilimab as neoadjuvant treatment for adult patients with stage IIB\u2011III resectable microsatellite instability\u2011high (MSI\u2011H) or mismatch repair deficient (dMMR) colon cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52147\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-29T04:51:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52147#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52147\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual\u2011IO Therapy for MSI\u2011H\\\/dMMR Colon Cancer\",\"datePublished\":\"2025-12-29T04:51:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52147\"},\"wordCount\":430,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Combination therapy\",\"HKG: 1801\",\"Immunotherapy\",\"Innovent Biologics\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52147#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52147\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52147\",\"name\":\"Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual\u2011IO Therapy for MSI\u2011H\\\/dMMR Colon Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2025-12-29T04:51:19+00:00\",\"description\":\"Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for TABOSUN (ipilimumab N01 injection; IBI310), a first\u2011in\u2011class domestic CTLA\u20114 monoclonal antibody, to be used in combination with the PD\u20111 inhibitor sintilimab as neoadjuvant treatment for adult patients with stage IIB\u2011III resectable microsatellite instability\u2011high (MSI\u2011H) or mismatch repair deficient (dMMR) colon cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52147#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52147\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52147#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual\u2011IO Therapy for MSI\u2011H\\\/dMMR Colon Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual\u2011IO Therapy for MSI\u2011H\/dMMR Colon Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for TABOSUN (ipilimumab N01 injection; IBI310), a first\u2011in\u2011class domestic CTLA\u20114 monoclonal antibody, to be used in combination with the PD\u20111 inhibitor sintilimab as neoadjuvant treatment for adult patients with stage IIB\u2011III resectable microsatellite instability\u2011high (MSI\u2011H) or mismatch repair deficient (dMMR) colon cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52147","og_locale":"en_US","og_type":"article","og_title":"Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual\u2011IO Therapy for MSI\u2011H\/dMMR Colon Cancer","og_description":"Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for TABOSUN (ipilimumab N01 injection; IBI310), a first\u2011in\u2011class domestic CTLA\u20114 monoclonal antibody, to be used in combination with the PD\u20111 inhibitor sintilimab as neoadjuvant treatment for adult patients with stage IIB\u2011III resectable microsatellite instability\u2011high (MSI\u2011H) or mismatch repair deficient (dMMR) colon cancer.","og_url":"https:\/\/flcube.com\/?p=52147","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-29T04:51:19+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52147#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52147"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual\u2011IO Therapy for MSI\u2011H\/dMMR Colon Cancer","datePublished":"2025-12-29T04:51:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52147"},"wordCount":430,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Combination therapy","HKG: 1801","Immunotherapy","Innovent Biologics","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52147#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52147","url":"https:\/\/flcube.com\/?p=52147","name":"Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual\u2011IO Therapy for MSI\u2011H\/dMMR Colon Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2025-12-29T04:51:19+00:00","description":"Innovent Biologics, Inc. (HKG: 1801) announced that China\u2019s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for TABOSUN (ipilimumab N01 injection; IBI310), a first\u2011in\u2011class domestic CTLA\u20114 monoclonal antibody, to be used in combination with the PD\u20111 inhibitor sintilimab as neoadjuvant treatment for adult patients with stage IIB\u2011III resectable microsatellite instability\u2011high (MSI\u2011H) or mismatch repair deficient (dMMR) colon cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52147#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52147"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52147#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual\u2011IO Therapy for MSI\u2011H\/dMMR Colon Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52147"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52147\/revisions"}],"predecessor-version":[{"id":52148,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52147\/revisions\/52148"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52147"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52147"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}